Stock listing
Munich:8E8 Elicera Therapeutics AB Aktie
German listing (Munich) of Elicera Therapeutics AB · home listing Stockholm:ELIC
Follow Elicera Therapeutics AB into a list and get an email when it puts out news.
Home listing price · OMXSTO:ELIC
2.62 SEK -0.05 (-2.1%)
Close on Nov 3, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:ELIC
- Day range
- 2.52 – 2.71 SEKNov 3, 2026
- Volume
- 295,914 sharesNov 3, 2026
- Market cap
- 174.5M SEKAt the close on Nov 3, 2026 · price × 66.74M shares outstanding
- 52-week range
- 2.25 – 7.00 SEKLowest and highest trades, Nov 4, 2025 – Nov 3, 2026
- Traded on an average day
- 923,819 SEKMedian day 208,745 shares · last 3 months, Aug 3, 2026 – Nov 3, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:ELIC · Home | 2.615 SEK | -0.055 (-2.1%) | 295,914 | 2.71 | 2.71 | 2.52 | 2.67 | Close on Nov 3, 2026 |
| Frankfurt:8E8 | €0.212 EUR | -0.006 (-2.5%) | — | €0.219 | €0.219 | €0.212 | €0.218 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 3, 2026 · OMXSTO:ELIC · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 2.615 | -0.055 | -2.1% | 2.71 | 2.71 | 2.52 | 295,914 | |
| 2.67 | +0.015 | +0.6% | 2.69 | 2.735 | 2.63 | 125,228 | |
| 2.655 | -0.085 | -3.1% | 2.75 | 2.795 | 2.645 | 79,479 | |
| 2.74 | -0.105 | -3.7% | 2.775 | 2.835 | 2.70 | 96,436 | |
| 2.845 | -0.01 | -0.4% | 2.85 | 2.85 | 2.76 | 87,112 | |
| 2.855 | +0.10 | +3.6% | 2.80 | 2.875 | 2.745 | 93,817 | |
| 2.755 | -0.045 | -1.6% | 2.795 | 2.825 | 2.72 | 107,164 | |
| 2.80 | 0.00 | 0.0% | 2.91 | 2.91 | 2.77 | 81,630 | |
| 2.80 | -0.085 | -2.9% | 2.885 | 2.905 | 2.80 | 98,442 | |
| 2.885 | +0.025 | +0.9% | 2.86 | 2.935 | 2.83 | 107,336 | |
| 2.86 | +0.01 | +0.4% | 2.90 | 2.90 | 2.82 | 88,055 | |
| 2.85 | -0.045 | -1.6% | 2.90 | 3.20 | 2.825 | 109,565 | |
| 2.895 | -0.095 | -3.2% | 2.895 | 2.99 | 2.85 | 168,726 | |
| 2.99 | -0.10 | -3.2% | 3.09 | 3.115 | 2.845 | 361,678 | |
| 3.09 | +0.15 | +5.1% | 2.955 | 3.14 | 2.88 | 334,453 | |
| 2.94 | +0.04 | +1.4% | 3.005 | 3.005 | 2.83 | 250,183 | |
| 2.90 | +0.145 | +5.3% | 2.705 | 3.23 | 2.68 | 1,269,814 | |
| 2.755 | -0.015 | -0.5% | 2.76 | 2.79 | 2.675 | 155,477 | |
| 2.77 | -0.065 | -2.3% | 2.78 | 2.78 | 2.71 | 135,501 | |
| 2.835 | +0.005 | +0.2% | 2.835 | 2.905 | 2.795 | 185,303 | |
| 2.83 | +0.055 | +2.0% | 2.77 | 2.86 | 2.695 | 87,382 | |
| 2.775 | -0.08 | -2.8% | 2.855 | 2.865 | 2.71 | 153,198 | |
| 2.855 | +0.07 | +2.5% | 2.785 | 2.865 | 2.75 | 193,402 | |
| 2.785 | +0.015 | +0.5% | 2.80 | 2.80 | 2.73 | 100,160 | |
| 2.77 | 0.00 | 0.0% | 2.77 | 2.82 | 2.735 | 127,922 | |
| 2.77 | +0.105 | +3.9% | 2.655 | 2.78 | 2.605 | 277,506 | |
| 2.665 | -0.05 | -1.8% | 2.72 | 2.74 | 2.66 | 366,095 | |
| 2.715 | -0.02 | -0.7% | 2.74 | 2.745 | 2.655 | 193,287 | |
| 2.735 | +0.025 | +0.9% | 2.655 | 2.765 | 2.61 | 71,568 | |
| 2.71 | -0.02 | -0.7% | 2.79 | 2.79 | 2.605 | 211,616 | |
| 2.73 | +0.015 | +0.6% | 2.72 | 2.895 | 2.685 | 230,611 | |
| 2.715 | -0.07 | -2.5% | 2.79 | 2.86 | 2.61 | 330,182 | |
| 2.785 | -0.02 | -0.7% | 2.835 | 2.835 | 2.715 | 112,310 | |
| 2.805 | -0.115 | -3.9% | 2.975 | 2.975 | 2.75 | 419,625 | |
| 2.92 | -0.055 | -1.8% | 2.97 | 2.97 | 2.835 | 119,239 | |
| 2.975 | -0.01 | -0.3% | 3.02 | 3.075 | 2.935 | 284,852 | |
| 2.985 | +0.105 | +3.6% | 2.875 | 3.02 | 2.775 | 389,480 | |
| 2.88 | +0.155 | +5.7% | 2.755 | 2.88 | 2.685 | 343,869 | |
| 2.725 | -0.115 | -4.0% | 2.83 | 2.83 | 2.71 | 141,265 | |
| 2.84 | +0.14 | +5.2% | 2.805 | 2.85 | 2.74 | 476,411 | |
| 2.70 | -0.13 | -4.6% | 2.765 | 2.785 | 2.645 | 132,440 | |
| 2.83 | -0.05 | -1.7% | 2.91 | 2.92 | 2.76 | 208,745 | |
| 2.88 | +0.02 | +0.7% | 2.86 | 2.89 | 2.81 | 305,094 | |
| 2.86 | +0.05 | +1.8% | 2.825 | 2.87 | 2.765 | 240,759 | |
| 2.81 | +0.15 | +5.6% | 2.705 | 2.85 | 2.66 | 230,763 | |
| 2.66 | -0.07 | -2.6% | 2.79 | 2.81 | 2.625 | 241,768 | |
| 2.73 | -0.12 | -4.2% | 2.855 | 2.86 | 2.70 | 408,868 | |
| 2.85 | +0.275 | +10.7% | 2.675 | 2.95 | 2.65 | 1,444,464 | |
| 2.575 | -0.07 | -2.6% | 2.685 | 2.70 | 2.575 | 182,247 | |
| 2.645 | -0.05 | -1.9% | 2.66 | 2.70 | 2.595 | 269,138 | |
| 2.695 | +0.07 | +2.7% | 2.66 | 2.70 | 2.595 | 169,939 | |
| 2.625 | +0.035 | +1.4% | 2.56 | 2.66 | 2.54 | 298,136 | |
| 2.59 | -0.01 | -0.4% | 2.54 | 2.60 | 2.505 | 302,790 | |
| 2.60 | -0.045 | -1.7% | 2.68 | 2.74 | 2.53 | 260,838 | |
| 2.645 | -0.04 | -1.5% | 2.675 | 2.765 | 2.58 | 306,739 | |
| 2.685 | -0.06 | -2.2% | 2.75 | 2.765 | 2.615 | 498,839 | |
| 2.745 | -0.125 | -4.4% | 2.88 | 2.88 | 2.68 | 540,607 | |
| 2.87 | -0.075 | -2.5% | 2.95 | 2.95 | 2.82 | 460,092 | |
| 2.945 | -0.02 | -0.7% | 3.045 | 3.05 | 2.84 | 397,160 | |
| 2.965 | +0.015 | +0.5% | 3.20 | 3.27 | 2.875 | 1,339,469 | |
| 2.95 | +0.455 | +18.2% | 2.43 | 3.33 | 2.41 | 3,611,140 | |
| 2.495 | -0.035 | -1.4% | 2.53 | 2.54 | 2.425 | 186,672 | |
| 2.53 | +0.145 | +6.1% | 2.33 | 2.53 | 2.32 | 528,995 | |
| 2.385 | +0.055 | +2.4% | 2.385 | 2.385 | 2.32 | 144,265 | |
| 2.33 | -0.02 | -0.9% | 2.35 | 2.395 | 2.32 | 103,573 | |
| 2.35 | +0.02 | +0.9% | 2.345 | 2.39 | 2.30 | 134,313 | |
| 2.33 | -0.06 | -2.5% | 2.395 | 2.41 | 2.29 | 170,026 |
- Ticker
- Munich:8E8
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Munich
- Currency
- EUR
What changed lately
Latest news release · Jun 1, 2026
Elicera announces outcome of the rights issue
Latest news
Elicera announces outcome of the rights issue
Jun 1, 2026
Closed 2.81 (-2.8%) on Jun 2, 2026
Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved
May 25, 2026
Closed 3.00 (-0.2%) on May 25, 2026
Elicera publishes information document regarding the rights issue
May 11, 2026
Closed 3.15 (-0.5%) on May 11, 2026
Elicera Therapeutics carries out a rights issue of approximately SEK 73 million
Apr 21, 2026
Closed 3.42 (-32.4%) on Apr 21, 2026
Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate
Mar 11, 2026
Closed 5.68 (-1.7%) on Mar 11, 2026
Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients
Mar 6, 2026
Closed 6.50 (-4.4%) on Mar 6, 2026
Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway
Feb 27, 2026
Closed 6.17 (-1.3%) on Feb 27, 2026
Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study
Feb 11, 2026
Closed 5.10 (+2.1%) on Feb 11, 2026
Elicera Therapeutics presents positive phase I/IIa data for ELC-100
Jan 9, 2026
Closed 5.92 (+13.8%) on Jan 9, 2026
Elicera Therapeutics AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 12 in the last 12 months · 12 in all · newest Jun 1, 2026 · oldest 2025
Where Elicera Therapeutics AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:ELIC · Home listing | Stockholm | Sweden | SEK |
| Frankfurt:8E8 | Frankfurt | Germany | EUR |
| gettex:8E8 | gettex | Germany | EUR |
| Munich:8E8 · This page | Munich | Germany | EUR |
| Stockholm:ELICBTA | Stockholm | Sweden | SEK |
Log in to ask 6ix AI your own questions about Elicera Therapeutics AB.